clinical trial · NCT05855967
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
Eli Lilly and Company·phase4·completed·n = 250
Plaque PsoriasisPsoriatic ArthritisIxekizumab
brief summary
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
started
Jun 27, 2023
primary completion
Aug 8, 2024
completion
Sep 23, 2024
last updated
Aug 22, 2025
official title
A 24-Week Multicenter, Open-label, Single-arm, Phase 4 Study to Evaluate the Safety of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis or Active Psoriatic Arthritis in India
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol